Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: Therapeutic implications

British Journal of Pharmacology

Volumn 168, Issue 3, 2013, Pages 519-533

  Toda, Noboru ^a   Nakanishi, Sadanobu ^b   Tanabe, Shinichi ^c  

^a Toyama Institute for Cardiovascular Pharmacology Research   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Social Insurance Kyoto Hospital   (Japan)

Author keywords

aldosterone; blood flow regulation; endothelial dysfunction; endothelin; mineralocorticoid receptor inhibitor; NO; T type Ca2+ channel

Indexed keywords

5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ALDOSTERONE; AMLODIPINE; ATRASENTAN; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CALCIUM ION; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; EPLERENONE; IMIDAPRIL; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE; SPIRONOLACTONE;

BIOAVAILABILITY; BIODEGRADATION; BIOSYNTHESIS; BLOOD FLOW; BLOOD VESSEL TONE; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FOREARM BLOOD FLOW; GENOMICS; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW; SODIUM BALANCE; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ALDOSTERONE; ANIMALS; BLOOD CIRCULATION; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III;

EID: 84872414046     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02194.x     Document Type: Review

References (124)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br. J. Pharmacol 164 (Suppl. 1): S1-S324.
2. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, et al. (2004). Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110: 2233-2240.
3. Andreis PG, Neri G, Tortorella C, Aragona F, Rossi GP, Nussdorfer GG, (2002). Mechanisms transducing the aldosterone secretagogue signal of endothelins in the human adrenal cortex. Peptides 23: 561-566.
4. Arima S, (2006). Aldosterone and the kidney: rapid regulation of renal microcirculation. Steroids 71: 281-285.
5. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F, et al. (2003). Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14: 2255-2263.
6. Arima S, Kohagura K, Xu HL, Sugawara A, Uruno A, Satoh F, et al. (2004). Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 43: 352-357.
7. Arrick DM, Mayhan WG, (2010). Inhibition of endothelin-1 receptors improves impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in type-1 diabetic rats. Microcirculation 17: 439-445.
8. Austin RC, Lentz SR, Werstuck GH, (2004). Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 11 (Suppl. 1): S56-S64.
9. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Lüscher TF, (1998). ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 31 (Pt 2): 499-504.
10. Bauersachs J, Heck M, Fraccarollo D, Hildemann SK, Ertl G, Wehling M, et al. (2002). Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39: 351-358.
11. Bayorh MA, Rollins-Hairston A, Adijiah J, Lyn D, Eatman D, (2011). Eplerenone suppresses aldosterone/salt-induced expression of NOX-4. J Renin Angiotensin Aldosterone Syst 12: 195-201.
12. Black SM, Johengen MJ, Solfer SJ, (1998). Coordinated regulation of genes of the nitric oxide and endothelin pathways during the development of pulmonary hypertension in fetal lambs. Pediatr Res 44: 821-830.
13. Böhm F, Jensen J, Svane B, Settergren M, Pernow J, (2008). Intracoronary endothelin receptor blockade improves endothelial function in patients with coronary artery disease. Can J Physiol Pharmacol 86: 745-751.
14. Bourque SL, Davidge ST, Adams MA, (2011). The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol 300: R1288-R1295.
15. Brown NJ, (2005). Aldposterone and end-organ damage. Curr Opin Nephrol Hypertens 14: 235-241.
16. Brunton L, (2011). Goodman & Gilman's Pharmacological Basis of Therapeutics, 12th edn. p. 1224. McGraw-Hill: New York.
17. Busse R, Flemming I, (1999). Nitric oxide, nitric oxide synthase and hypertensive vascular disease. Curr Hypertens Rep 1: 88-95.
18. Di Francescomarino S, Sciartilli A, Di Valerio V, Di Baldassarre A, Gallina S, (2009). The effect of physical exercise on endothelial function. Sports Med 39: 797-812.
19. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM, (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
20. Dorrance AM, Osborn HL, Grekin R, Webb RC, (2001). Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol 281: R944-R950.
21. Duffy SJ, Biegelsen ES, Eberhardt RT, Kahn DF, Kingwell BA, Vita JA, (2005). Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 46: 707-713.
22. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL, (2004). Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43: 1252-1257.
23. Enseleit F, Lüscher T, Ruschitzka F, (2010). Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension. Ther Adv Cardiovasc Dis 4: 231-240.
24. Francois M, Kojda G, (2004). Effects of hypercholesterolemia and oxidative stress on the nitric oxide-cyclic GMP pathway. Neurochem Int 45: 955-961.
25. Farquharson CA, Struthers AD, (2000). Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101: 594-597.
26. Farquharson CA, Struthers AD, (2002). Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 103: 425-431.
27. Félétou M, Huang Y, Vanhoutte PM, (2010). Vasoconstrictor prostanoids. Pflügers Arch 459: 941-950.
28. Ferri C, Bellini C, Desideri G, Mazzocchi C, De Siati L, Santucci A, (1997). Elevated plasma and urinary endothelin-1 levels in human salt-sensitive hypertension. Clin Sci (Lond) 93: 35-41.
29. Förstermann U, Pollock JS, Schmidt HH, Heller M, Murad F, (1991). Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 88: 1788-1792.
30. Fujita M, Minamino T, Asanuma H, Sanada S, Hirata A, Wakeno M, et al. (2005). Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathway in hypoperfused canine hearts. Hypertension 46: 113-117.
31. Furchgott RF, (1988). Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In:, Vanhoutte PM, (ed.). Vasodilatation: Vascular Smooth Muscle, Pepties, Autonomic Nerve and Endothelium. Raven Press, Ltd: New York, pp. 401-414.
32. Furchgott RF, Zawadzki JV, (1980). Obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376.
33. Gandhi SK, Ryder DH, Brown NJ, (1996). Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 28: 961-966.
34. Garthwaite J, Southam E, Boulton CL, Nedlsen EB, Schmidt K, Mayer B, (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo]4,3-a]quinoxalin-1-one. Mol Pharmacol 48: 184-188.
35. Golestaneh N, Klein C, Valmanesh F, Suarez G, Agarwal MK, Mirshahi M, (2001). Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channels in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Commun 280: 1300-1306.
36. Gromotowicz A, Szemaj J, Stankiewicz A, Zakrzeska A, Mantur M, Jaroszewicz E, et al. (2011). Study of the mechanisms of aldosterone prothrombotic effect in rats. J Renin Angiotensin Aldosterone Syst 12: 430-439.
37. Gunaruwan P, Schmitt M, Taylor J, Lee L, Struthers A, Frenneaux M, (2002). Lack of rapid aldosterone effects on forearm resistance vasculature in health. J Renin Angiotensin Aldosterone Syst 3: 123-125.
38. Gunaruwan P, Schmitt M, Sharman J, Lee L, Struthers A, Frenneaux M, (2005). Effects of aldosterone on forearm vasculature in treated chronic heart failure. Am J Cardiol 95: 412-414.
39. Halcox JP, Nour KR, Zalos G, Quyyumi AA, (2001). Coronary vasodilatation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ Res 89: 969-976.
40. Hao L, Kanno Y, Fukushima R, Watanabe Y, Ishida Y, Suzuki H, (2004). Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. Am J Nephrol 24: 54-60.
41. Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y, (2006). Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol 47: 609-613.
42. Heylen E, Huang A, Sun D, Kaley G, (2009). Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone. J Cardiovasc Pharmacol 54: 535-542.
43. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL, (2004). Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system. Am J Hypertens 17: 597-603.
44. Imagawa K, Okayama S, Takaoka M, Kawata H, Naya N, Nakajima T, et al. (2006). Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 47: 133-138.
45. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y, (2008). Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 149: 1009-1014.
46. Kitagawa K, Oku N, Kimura Y, Yagita Y, Sakaguchi M, Hatazawa J, et al. (2009). Relationship between cerebral blood flow and later cognitive decline in hypertensive patients with cerebral small vessel disease. Hypertens Res 32: 816-820.
47. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, et al. (2006). Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 47: 671-679.
48. Kusche-Vihrog K, Callies C, Fels J, Oberleithner T, (2010). The epithelial sodium channel (ENaC): mediator of the aldosterone response in the vascular endothelium? Steroids 75: 544-549.
49. Lalevée N, Rebsamen MC, Barrére-Lemaire S, Perrier E, Nargeot J, Bénitah JP, et al. (2005). Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 67: 216-224.
50. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, et al. (2007). Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13: 189-197.
51. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD, (2003). Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108: 2400-2406.
52. Macleod MR, Johansson IM, Söderström I, Lai M, Gidö G, Weloch T, et al. (2003). Mineralocorticoid receptor expression and increased survival following neuronal injury. Eur J Neurosci 17: 1549-1555.
53. Maeda S, Miyauchi T, Iemitsu M, Tanabe T, Goto K, Yamaguchi I, et al. (2004). Endothelin receptor antagonist reverses decreased NO system in the kidney in vivo during exercise. Am J Physiol 286: E609-E614.
54. 2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 146: 973-980.
55. Michell BJ, Chen ZP, Tiganis T, Stapleton D, Katsis F, Power DA, et al. (2001). Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 276: 17625-17628.
56. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, et al. (2005). Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16: 2906-2912.
57. Moncada S, Vane JR, (1981). Prostacyclin: its biosynthesis, actions, and clinical potential. Philos Trans R Soc Lond B Biol Sci 294: 305-329.
58. Moncada S, Palmer RM, Higgs EA, (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
59. Mutoh A, Isshiki M, Fujita T, (2008). Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells. Hypertens Res 31: 1811-1820.
60. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, et al. (2006). Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 48: 165-171.
61. Nietlispach F, Julius B, Schindler R, Bernheim A, Binkert C, Kiowski W, et al. (2007). Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension 50: 82-88.
62. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA, (2004). Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 109: 2857-2861.
63. Oberleithner H, (2005). Aldosterone makes human endothelium stiff and vulnerable. Kidney Int 67: 1680-1682.
64. Oberleithner H, Riethmüller C, Ludwig T, Hausberg M, Schillers H, (2006a). Aldosterone remodels human endothelium. Acta Physiol (Oxf) 187: 305-312.
65. Oberleithner H, Riethmüller C, Ludwig T, Shahin V, Stock C, Schwaab A, et al. (2006b). Differential action of steroid hormones on human endothelium. J Cell Sci 119: 1926-1932.
66. Oberleithner H, Riethmüller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M, (2007). Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA 104: 16281-16286.
67. Ohmine T, Miwa Y, Takahashi-Yanaga F, Morimoto S, Maehara Y, Sasaguri T, (2009). The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells. Hypertens Res 32: 690-699.
68. Ohtani K, Usui S, Kaneko S, Takashima S, Kitano K, Yamamoto K, et al. (2012). Benidipine reduces ischemia reperfusion-induced systemic oxidative stress through suppression of aldosterone production in mice. Hypertens Res 35: 287-294.
69. Okamura H, Doi M, Yamaguchi Y, Fustin JM, (2011). Hypertension due to loss of clock: novel insight from the molecular analysis of Cry1/Cry2-deleted mice. Curr Hypertens Rep 13: 103-108.
70. Okayama S, Imagawa K, Naya N, Iwama H, Somekawa S, Kawata H, et al. (2006). Blocking T-type Ca2+ channels with efonidipine decreases plasma aldosterone concentration in healthy volunteers. Hypertens Res 29: 493-497.
71. Osmond J, Rigsby CS, Dorrance AM, (2008). Is the mineralocorticoid receptor a potential target for stroke prevention? Clinical Sci 114: 37-47.
72. Palmer RM, Ferrige AG, Moncada S, (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526.
73. Park JB, Schiffrin EL, (2001). ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 37: 1444-1449.
74. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717.
75. Pojoga LH, Adamova Z, Kumar A, Stennett AK, Romero JR, Adler GK, et al. (2010). Sensitivity of NOS-deficient vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1 deficient mice. Am J Physiol 298: H1776-H1788.
76. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL, (2003). Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42: 49-55.
77. Quaschning T, Ruschitzka F, Niggi B, Lunt CM, Shaw S, Wehling M, et al. (2001a). Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. Nephrol Dial Transplant 16: 2146-2151.
78. Quaschning T, Ruschitzka F, Shaw S, Lüscher TF, (2001b). Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37 (2 Part 2): 801-805.
79. Rajagopalan S, Duquaine D, King S, Pitt B, Patal P, (2002). Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105: 2212-2216.
80. Ramzy D, Rao V, Tumiati LC, Xu N, Sheshgiri R, Miriuka S, et al. (2006). Elevated endothelin-1 levels impair nitric oxide homeostasis through a PKC-dependent pathway. Circulation 114 (1 Suppl.): 1319-1326.
81. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, et al. (2010). Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 122: 958-966.
82. Rigsby CS, Dorrance AM, (2004). Spironolactone increases lumen diameter in the middle cerebral artery of spontaneously hypertensive stroke-prone rats (SHRSP). Hypertension 44: 536.
83. Rigsby CS, Cannady WE, Dorrance AM, (2005). Aldosterone: good guy or bad guy in cerebrovascular disease? Trends Endocrinol Metab 16: 401-406.
84. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr, (1998). Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451-458.
85. Rodríguez-Pascual F, Busnadiego O, Lagares D, Lamas S, (2011). Role of endothelin in the cardiovascular system. Pharmacol Res 63: 463-472.
86. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V, (2003). Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166: 345-349.
87. 2+ in human adrenocortical carcinoma NCI-H295 cells. Endocrinology 138: 4421-4426.
88. Rossi GP, Albertin G, Neri G, Andreis PG, Hofmann S, Pessina AC, et al. (1997b). Endothelin-1 stimulates steroid secretion of human adrenocortical cells ex vivo via both ETA and ETB receptor subtypes. J Clin Endocrinol Metab 82: 3445-3449.
89. Rossi GP, Carvallin M, Nussorfer GG, Pessina AC, (2001). The endothelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol 38 (Suppl. 2): S49-S52.
90. Rossi GP, Ganzaroli C, Cesari M, Maresca A, Plebani M, Nussdorfer GG, et al. (2003). Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovasc Res 57: 277-283.
91. Rossier MF, Ertel EA, Vallotton MB, Capponi AM, (1998). Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cell. J Pharmacol Exp Ther 287: 824-831.
92. Rossier MF, Lesouhaitier O, Perrier E, Bockhom L, Chiappe A, Lelevée N, (2003). Aldosterone regulation of T-type calcium channels. J Steroid Biochem Mol Biol 85: 383-388.
93. Ruschitzka F, Quaschning T, Noll G, de Gottardi A, Rossier MF, Enseleit F, et al. (2001). Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11β-hydoxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation 103: 3129-3135.
94. Sanz-Rosa D, Oubiňa MP, Cediel E, De las Heras N, Aragoncillo P, Balfagón G, et al. (2005). Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid Redox Signal 7: 1294-1301.
95. Sato A, Fukuda S, (2010). Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 24: 387-394.
96. Schiffrin EL, (2006). Effects of aldosterone on the vasculature. Hypertension 47: 312-318.
97. Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, et al. (2003). Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 42: 156-160.
98. Schmidt BM, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE, (2006). Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 47: 650-655.
99. Schmitt M, Gunaruwan P, Frenneaux MP, (2004). Rapid nongenomic aldosterone effects in the human forearm? Hypertension 43: e1.
100. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. (2011). Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 121: 3233-3243.
101. Skøtt O, Uhrenholt TR, Schjeming J, Hansen PB, Rasmussen LE, Jensen BL, (2006). Rapid actions of aldosterone in vascular health and disease-friend or foe? Pharmacol Ther 111: 495-507.
102. Takeda Y, (2009). Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hypertens Res 32: 321-324.
103. Takeda Y, Zhu A, Yoneda T, Usukura M, Takata H, Yamagishi M, (2007). Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl-salt-sensitive hypertensive rats. Am J Hypertens 20: 1119-1124.
104. Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T, Horie M, (2007). Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens Res 30: 691-697.
105. Thai HM, Do BQ, Tran TD, Gaballa MA, Goldman S, (2006). Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail 12: 240-245.
106. Toda N, (2012). Age-related changes in endothelial function and blood flow regulation. Pharmacol Ther 133: 159-176.
107. Toda N, Arakawa K, (2011). Salt-induced hemodynamic regulation mediated by nitric oxide. J Hypertens 29: 415-424.
108. Toda N, Ayajiki K, (2010). Vascular actions of nitric oxide as affected by exposure to alcohol. Alcohol Alcohol 45: 347-355.
109. Toda N, Nakanishi-Toda M, (2011). How mental stress affects endothelial function. Pflügers Arch Eur. J Physiol 462: 779-794.
110. Toda N, Okamura T, (2012). Cerebral blood flow regulation by nitric oxide in Alzheimer's disease. J Alzheimer Dis 32: 569-578.
111. Toda N, Toda H, (2010). Nitric oxide-mediated blood flow regulation as affected by smoking and nicotine. Eur J Pharmacol 649: 1-13.
112. Toda N, Imamura T, Okamura T, (2010). Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus. Pharmacol Ther 127: 189-209.
113. Tsuchiya K, Yoshimoto T, Hirata Y, (2009). Endothelial dysfunction is related to aldosterone excess and raised blood pressure. Endocr J 56: 533-539.
114. Tsutamoto T, Tanaka T, Nishiyama K, Yamaji M, Kawahara C, Fujii M, et al. (2009). Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hypertens Res 32: 670-674.
115. Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira-Melo S, Coelho OR, et al. (2009). Aldosterone excess or escape: treating resistant hypertension. J Clin Hypertens (Greenwich) 11: 245-252.
116. Uhrenholt TR, Schjerning J, Hansen PB, N nrregaard R, Jensen BL, Sorensen GL, et al. (2003). Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 93: 1258-1266.
117. Uhrenholt TR, Schjerning J, Rasmussen LE, Hansen PB, N ø ′ nrregaard R, Jensen BL, et al. (2004). Rapid non-genomic effects of aldosterone on rodent vascular function. Acta Physiol Scand 181: 415-419.
118. Verhovez A, Zeoli A, Williams TA, Morello F, Brizzi MF, Veglio F, et al. (2008). Primary aldosteronism (PA) and endothelial progenitor cell (EPC) bioavailability. Clin Endocrinol (Oxf) 69: 528-534.
119. Virdis A, Naves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL, (2002). Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40: 504-510.
120. Wedgwood S, Black SM, (2005). Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol 288: L480-L487.
121. White K, Reitenbach I, Stolpe K, Schilling L, Kirchengast M, Lammer B, (2003). Effects of the endothelin a receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats. J Cardiovasc Pharmacol 41: 890-896.
122. Wong S, Brennan FE, Young MJ, Fuller PJ, Cole TJ, (2007). A direct effect of aldosterone on endothelkin-1 gene expression in vivo. Endocrinology 148: 1511-1517.
123. Yagi S, Akaike M, Aihara K, Iwase T, Yoshida S, Sumitomo-Ueda Y, et al. (2011). High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res 34: 74-78.
124. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. (1988). A Novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415.